<DOC>
	<DOCNO>NCT00005968</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient stage IV melanoma .</brief_summary>
	<brief_title>Irofulven Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate duration response patient stage IV malignant melanoma treat 6-hydroxymethylacylfulvene . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive 6-hydroxymethylacylfulvene IV 5 minute day 1-5 . Treatment repeat every 4 week minimum 2 course absence disease progression unacceptable toxicity . Patients stable respond disease completion course 2 receive additional course . Patients follow every 3 month 5 year , annually thereafter death . PROJECTED ACCRUAL : Approximately 16-35 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IV malignant melanoma No prior chemotherapy OR No 1 prior chemotherapy contain regimen Measurable disease Brain metastasis allow adequately treated PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 10 g/dL WBC least 4,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) ALT/AST great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No concurrent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2002</verification_date>
	<keyword>stage IV melanoma</keyword>
</DOC>